Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston
02 Settembre 2021 - 5:45PM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced that Elizabeth Woo has joined the Company as Senior Vice
President, Investor Relations, Public Relations and Corporate
Communications, based in the Boston area.
“We are delighted to welcome Elizabeth to Poxel in a senior
leadership role as we continue to advance the Company and grow our
US presence,” said Thomas Kuhn, CEO of Poxel. “Elizabeth has a long
history of working with the biotechnology financial community and a
strong track record of raising the visibility to help build
successful biopharmaceutical companies in the US. Elizabeth will
also work closely with members of the leadership team headquartered
in France.”
“Poxel is at an important inflection point as the Company
expands development and commercialization efforts into rare
diseases, complementing its existing platforms in NASH, which are
both therapeutic areas that leverage Poxel’s metabolic
pathophysiology expertise and heritage,” commented Ms. Woo. “I am
excited to work with the experienced team at Poxel as the Company
approaches multiple key data readouts anticipated over the next 12
to 18 months.”
Ms. Woo has 25 years of experience in the biopharmaceutical
industry. Her experience in strategic investor and corporate
communications spans the full life cycle of drug development and
commercialization. Early in her career at Biogen, she held a series
of progressively responsible management and executive roles over a
12-year period and served as Vice President, Investor Relations.
Ms. Woo also served as Senior Vice President, Investor Relations
and Corporate Communications at Flex Pharma. In addition to her
corporate roles, she has advised, through her investor relations
consulting practice, privately held and publicly traded biotech
companies, including Ironwood and Cubist. Ms. Woo obtained an MBA
from the Kellogg School of Management and holds a Bachelor of
Science in biochemistry from the University of California,
Berkeley.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing
innovative treatments for chronic serious diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare disorders. Poxel has clinical and earlier-stage programs from
its adenosine monophosphate-activated protein kinase (AMPK)
activator and deuterated TZD platforms targeting chronic and rare
metabolic diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY). PXL770, a first-in-class direct AMPK activator,
has successfully completed a Phase 2a proof-of-concept trial for
the treatment of NASH, which met its objectives. For the rare
inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG (Imeglimin), Poxel’s first-in-class lead product that
targets mitochondrial dysfunction, has been approved for the
treatment of type 2 diabetes in Japan. With this approval, Poxel is
entitled to receive milestones, sales-based payments and royalties
from Sumitomo Dainippon Pharma. Poxel has a strategic partnership
with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South
Korea, Taiwan and nine other Southeast Asian countries. The Company
intends to generate further growth through strategic partnerships
and pipeline development. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210902005541/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78
Elizabeth Woo Senior Vice President, Investor Relations
& Communication elizabeth.woo@poxelpharma.com
Investor relations / Media - EU/US Trophic Communications
Stephanie May or Valeria Fisher poxel@trophic.eu +49 171 185 56 82
or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh
or Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024